Phase 2 Data Published Online in Nature Communications
September 21, 2021
Learn more
SHENZHEN, CHINA and ROCKVILLE, MD, September 13, 2021 — HighTide Therapeutics Inc. (“HighTide”), a clinical-stage biopharmaceutical company, announced that the first group of patients have been enrolled and dosed in a PK bridging stu
September 10, 2021
Learn more
HighTide Therapeutics Inc. (“HighTide”), a clinical-stage biopharmaceutical company, today announced the topline results of the study of HTD1801 in primary sclerosing cholangitis (PSC) will be presented at the International Liver Congress 2021, 23-26 June
June 22, 2021
Learn more
We will contact you as soon as possible
© 2020 HighTide Therapeutics Inc.